MIPS
Forward Health Group is approved by the Centers for Medicare and Medicaid Services (CMS) as a Qualified Registry (QR) and as a Qualified Clinical Data Registry (QCDR) for the CMS Merit-Based Incentive Payment System (MIPS) for 2024.
Both the QR and the QCDR are approved to report all quality measures available under MIPS. The QCDR offers six additional quality measures for reporting, designed specifically to support quality improvement/reporting in the renal/nephrology space. Clinicians and practices that use PopulationManager® as part of the reporting tracking and submission can also earn significant “bonus” points under MIPS that increase reimbursement, avoid payment penalties, and decrease staff & technology expenses.
Forward Health Group’s robust Data Stewardship™ process enables practices with cumbersome, time-consuming EHR implementations to forego the next upgrade cycle and still report for the entire calendar year.
PopulationManager is the only solution on the market that maximizes data from all sources—EHRs, payor claims, practice management platforms, labs, patient captured results—and delivers clinician engagement through clinically intuitive performance measurement.
The Renal and Vascular Outcomes Improvement Program, powered by Forward Health Group, was approved by the Centers for Medicare and Medicaid Services (CMS) as a Qualified Clinical Data Registry (QCDR) for the CMS Merit-Based Incentive Payment System (MIPS) for 2023.
Six Non-MIPS measures were approved for inclusion in the Quality Renal Registry QCDR. Organizations can also report on any of the 2023 MIPS Quality Measures through Forward Health Group’s QCDR or approved Qualified Registry.
